UNSPSC 51263174: Timolol hemihydrate

This classification denotes a beta-adrenergic blocking agent with the molecular formula 2C13H24N4O3S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 817W3C6175, chemically known as (s)-1-(tert-butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)-2-propanol hemihydrate, but more generally known as timolol hemihydrate, which bears US NIH Compound Identifier 62933. European Medicines Agency schedules timolol hemihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11069MIG.

Most nations, for tariff purposes, schedule timolol hemihydrate under HS 29349990. SMILES: CC(C)(C)NC[C@@H](COC1C(NSN1)N2CCOCC2)O.CC(C)(C)NC[C@@H](COC1C(NSN1)N2CCOCC2)O.O.

UNSPSC 51263174 Timolol hemihydrate is a Commodity code for a specific ophthalmic and systemic beta-blocker pharmaceutical ingredient, but the recent state and local opportunities posted under this code do not reflect purchases of timolol or related ophthalmologic agents. Instead, the tagged solicitations center on naloxone procurement and pharmacy benefit management strategy — a clear mismatch between the code's nominal scope and the work actually being bought. State and local government buying activity under this code shows little relevant recent procurement aligned with the pharmaceutical chemical itself.

The two posted opportunities target different customer segments and procurement phases. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive sealed bidding, with a response deadline of July 26, 2023 and quarterly deliveries to the Seminole County Community Health Building in Sanford; the contract carries a two-year initial term plus one-year renewal option and includes FEMA compliance requirements. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, soliciting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program — an exploratory market-intelligence phase aimed at establishing direct relationships between state pharmacy programs and manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. Neither opportunity involves timolol procurement, suggesting this code may have been assigned in error or reflects a data-tagging artifact rather than genuine state and local demand for the commodity itself.